Complete Filing Data
Telix Pharmaceuticals Ltd reported Cash And Cash Equivalents of $141.87 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Telix Pharmaceuticals Ltd did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Sales And Marketing Expense | $96.8M | $56.0M | $33.5M | $36.3M |
| Revenue From Contracts With Customers | $803.8M | $516.6M | $333.0M | $160.1M |
| Research And Development Expense | $171.2M | $127.9M | $85.3M | $80.7M |
| Profit Loss From Operating Activities | $29.8M | $55.2M | $11.0M | -$91.9M |
| Profit Loss Before Tax | -$5.3M | $37.9M | $2.6M | -$98.6M |
| Profit Loss Attributable To Owners Of Parent | -$7.1M | $33.7M | $4.2M | -$104.1M |
| Profit Loss | -$7.1M | $33.7M | $4.2M | -$104.1M |
| Other Comprehensive Income Net Of Tax Gains Losses From Investments In Equity Instruments | -$1.2M | -$3.3M | -$612.0K | $0.00 |
| Other Comprehensive Income Net Of Tax Exchange Differences On Translation | -$5.8M | $5.6M | -$1.9M | $591.0K |
| Other Comprehensive Income | -$7.0M | $2.3M | -$2.5M | $591.0K |
| Income Taxes Paid Refund Classified As Operating Activities | $21.3M | $2.0M | $6.9M | $2.3M |
| Income Tax Expense Continuing Operations | $1.9M | $4.2M | -$1.6M | $5.5M |
| Gross Profit | $426.4M | $336.2M | $209.5M | $94.9M |
| General And Administrative Expense | $95.8M | $85.3M | $49.7M | $47.2M |
| Cost Of Sales | $377.4M | $180.4M | $123.4M | $65.2M |
| Comprehensive Income Attributable To Owners Of Parent | -$14.1M | $36.0M | $1.7M | -$103.5M |
| Comprehensive Income | -$14.1M | $36.0M | $1.7M | -$103.5M |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash And Cash Equivalents | $141.9M | $440.0M | $84.3M | $78.8M | $22.0M |
| Rightofuse Assets | $57.0M | $5.8M | $5.0M | $6.8M | |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $25.7M | $9.1M | $6.3M | $7.0M | |
| Purchase Of Other Longterm Assets Classified As Investing Activities | $12.2M | $8.4M | $0.00 | $0.00 | |
| Purchase Of Intangible Assets Classified As Investing Activities | $18.1M | $13.1M | $802.0K | $6.8M | |
| Purchase Of Decommissioning Liability Classified As Investing Activities | $0.00 | $0.00 | $37.0K | $2.2M | |
| Property Plant And Equipment | $58.7M | $27.8M | $15.8M | $12.0M | |
| Issue Of Equity | $31.8M | $93.5M | $21.8M | $175.0M | |
| Increase Decrease Through Transfer On Exercise Of Options Equity | $0.00 | $0.00 | $0.00 | $0.00 | |
| Increase Decrease Through Share Based Payment Transactions Associated With Acquisitions Equity | $23.3M | $44.9M | $14.2M | $0.00 | |
| Changes In Equity | $76.6M | $214.3M | $46.1M | $181.3M | |
| Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities | $220.7M | $20.7M | $0.00 | $973.0K | |
| Cash Flows From Used In Operating Activities | -$17.3M | $27.5M | $14.3M | -$64.0M | |
| Cash Flows From Used In Investing Activities | -$285.9M | -$86.7M | -$16.8M | -$17.0M | |
| Cash Flows From Used In Financing Activities | -$3.7M | $416.8M | $7.1M | $175.0M | |
| Trade And Other Current Receivables | $129.2M | $86.9M | $44.0M | ||
| Trade And Other Current Payables | $150.3M | $86.8M | $54.3M | ||
| Retained Earnings | -$154.5M | -$152.9M | -$187.1M | ||
| Other Noncurrent Assets | $28.8M | $15.1M | $277.0K | ||
| Other Current Assets | $16.1M | $13.7M | $12.4M | ||
| Noncurrent Liabilities | $517.0M | $382.4M | $63.2M | ||
| Noncurrent Lease Liabilities | $56.5M | $5.0M | $5.3M | ||
| Noncurrent Financial Assets | $37.1M | $34.7M | $8.4M | ||
| Noncurrent Contract Liabilities | $0.00 | $2.0M | $8.3M | ||
| Noncurrent Assets | $833.7M | $370.3M | $118.6M | ||
| Net Assets Liabilities | $415.4M | $352.9M | $102.6M | ||
| Liabilities | $748.6M | $587.4M | $174.6M | ||
| Intangible Assets And Goodwill | $592.8M | $257.9M | $75.1M | ||
| Deferred Tax Liabilities | $44.7M | $5.8M | $0.00 | ||
| Deferred Tax Assets | $59.4M | $28.9M | $14.0M | ||
| Current Tax Liabilities Current | $30.7M | $30.1M | $13.1M | ||
| Current Tax Assets Current | $6.0M | $5.9M | $5.2M |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Proceeds From Issuing Other Equity Instruments | $1.8M | $662.0K | $4.2M | $181.0M |
| Proceeds From Borrowings Classified As Financing Activities | $529.0K | $427.9M | $4.2M | $3.0M |
| Payments To Suppliers For Goods And Services And To And On Behalf Of Employees | $710.6M | $418.3M | $280.4M | $204.3M |
| Payments Of Lease Liabilities Classified As Financing Activities | $5.2M | $1.3M | $1.3M | $1.3M |
| Payments For Debt Issue Costs | $0.00 | $9.7M | $0.00 | $7.8M |
| Payments For Contingent Consideration Classified As Operating Activities | $51.8M | $23.9M | $10.9M | $0.00 |
| Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes | -$306.9M | $357.6M | $4.5M | $94.0M |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | $8.8M | -$1.9M | $992.0K | $299.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Diluted Earnings Loss Per Share From Continuing Operations | $-0.02 | $0.10 | $0.01 | $-33.50 |
| Basic Earnings Loss Per Share From Continuing Operations | $-0.02 | $0.10 | $0.01 | $-33.50 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Repayments Of Borrowings Classified As Financing Activities | $819.0K | $745.0K | $0.00 | $13.0K |
| Receipts From Sales Of Goods And Rendering Of Services | $774.2M | $467.7M | $311.8M | $124.1M |
| Purchase Of Financial Instruments Classified As Investing Activities | $892.0K | $32.9M | $8.7M | $0.00 |
| Purchase Of Contingent Consideration Classified As Investing Activities | $7.7M | $2.5M | $995.0K | $0.00 |
| Other Gains Losses | $11.7M | $4.9M | -$23.8M | -$18.8M |
| Manufacturing And Distribution Costs | $44.6M | $16.7M | $6.3M | $3.9M |
| Interest Received Classified As Operating Activities | $5.8M | $7.2M | $1.1M | $1.0K |
| Interest Paid Classified As Operating Activities | $13.7M | $3.1M | $385.0K | $408.0K |
| Increase Decrease Through Sharebased Payment Transactions | $19.4M | $12.9M | $5.8M | $8.1M |
| Increase Decrease Through Exercise Of Options | $2.2M | $660.0K | $4.3M | $6.0M |
| Finance Income | $5.8M | $7.2M | $671.0K | $1.0K |
| Finance Costs | $40.9M | $24.4M | $9.1M | $6.7M |
| Shortterm Borrowings | $13.1M | $11.8M | $660.0K | |
| Other Reserves | $101.6M | $75.9M | $16.3M | |
| Noncurrent Provisions | $9.2M | $8.5M | $5.5M | |
| Non Current Employee Benefit Obligations | $444.0K | $305.0K | $212.0K | |
| Non Current Contingent Consideration | $10.7M | $18.8M | $38.0M | |
| Longterm Borrowings | $391.9M | $341.8M | $5.9M | |
| Issued Capital | $480.0M | $414.0M | $315.2M | |
| Inventories | $37.1M | $23.6M | $12.7M |
Most recent annual filing with the SEC: February 20, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.